Rolf Stahel

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade.

Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA

Part of GSK Plc, Wellcome Plc is a British company that specializes in the discovery, development, manufacture, and sale of human healthcare products. The company is based in Greenford, UK.

Cosmo Pharmaceuticals SA operates as a pharmaceutical company that engages in the manufacturing of pharmaceutical drugs. It focuses on the development of gastro-intestinal pharmaceutical products for the treatment of inflammatory bowel diseases, colon infections and colon diagnosis, and treated skin disorders. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Lainate, Italy.

PowderMed Ltd. develops immunotherapeutic products. It focuses on the clinical development and manufacture of therapeutic and prophylactic DNA-based vaccines for viral diseases and cancer. The company has 4 clinical and 3 pre-clinical stage projects. The company was founded February 25, 2004 by Dr. Clive Dix & Dr. Beadle and is headquartered at Oxford, The United Kingdom.